BioCentury's websites will be down for upgrades starting at 9 p.m. PDT on Monday, August 26. We expect the downtime to last no more than 6 hours, and we apologize for any inconvenience.

12:00 AM
Apr 04, 2011
 |  BC Week In Review  |  Company News  |  Deals

Cephalon, Valeant Pharmaceuticals deal

Valeant made public an unsolicited offer to acquire cancer and neurology company Cephalon for $73 per share in cash, or about $5.7 billion. The price is a 24% premium to Cephalon's close of $58.75 on March 29, before the deal was announced. Valeant also said it will seek to replace Cephalon's board of directors with its own nominees. Valeant said...

Read the full 277 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >